北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科  > 期刊论文
学科主题: 临床医学
题名:
Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension
作者: Sun, Ning-L.2; Zhu, Jun-R.1; Zhao, Yanxing3; Tu, Ying-M.4; Co-Diovan Trial Investigators
关键词: Chinese population ; Combination therapy ; Hydrochlorothiazide ; Hypertension ; Valsartan
刊名: CURRENT MEDICAL RESEARCH AND OPINION
发表日期: 2008
DOI: 10.1185/03007990802390647
卷: 24, 期:10, 页:2863-2871
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal ; Medicine, Research & Experimental
研究领域[WOS]: General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]: BLOOD-PRESSURE ; JNC-VII ; MANAGEMENT ; VALSARTAN/HYDROCHLOROTHIAZIDE ; GUIDELINES ; EFFICACY ; MONOTHERAPY ; PREVALENCE ; PREVENTION ; DIFFERENCE
英文摘要:

Objectives: To compare the efficacy and safety of valsartan (VAL)/ HCTZ 80/12.5 mg with VAL 80 mg in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with VAL 80 mg alone.

Research design and methods: This was a multicenter, double-blind, double-dummy, randomized, active-controlled, parallel-group trial. Patients (1175) with mild-to-moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP] >= 95 and < 110 mmHg) from 26 centers in China received VAL 80 mg o.d. for 4 weeks, 864 patients whose MSDBP remained >= 90 and < 110 mmHg were randomized (1:1) to receive VAL80/ HCTZ12.5 mg (n = 429) or VAL80 mg (n = 435) for 8 weeks.

Main outcome measures: The efficacy variable was changed from baseline to endpoint in trough MSDBP. The secondary efficacy variables were changed in mean sitting systolic blood pressure (MSSBP), response rate, and control rate.

Results: Significant reductions in MSDBP and MSSBP from baseline to endpoint were observed in both groups. There were significantly greater reductions in MSDBP (8.4 mmHg vs. 6.2 mmHg) and MSSBP (10.2 mmHg vs. 6.7 mmHg), higher response (64.2% vs. 52.5%) and control rates (53.9% vs. 40.9%) in the VAL80/HCTZ12.5 group as compared with the VAL80 group at endpoint (p < 0.001). VAL80/HCTZ12.5 was equally effective in both age subgroups (>= 65 and < 65 years) and was well tolerated. There were no deaths and the two serious adverse events reported were unrelated to study medication.

Conclusion: In Chinese patients with mild-to-moderate essential hypertension not adequately controlled by VAL 80 mg alone, VAL80/HCTZ12.5 mg combination was well tolerated and showed additional BP reduction. The limitations of this study were the inability to include an HCTZ arm as a control group and the short trial duration.

Trial registration: NCT00250562.

语种: 英语
项目资助者: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
WOS记录号: WOS:000260261100016
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/59674
Appears in Collections:北京大学第二临床医学院_心血管内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200032, Peoples R China
2.Beijing Univ, Peoples Hosp, Dept Cardiol, Beijing 100871, Peoples R China
3.Novartis Pharmaceut Corp, E Hanover, NJ USA
4.Beijing Novartis Pharma Co Ltd, Beijing, Peoples R China

Recommended Citation:
Sun, Ning-L.,Zhu, Jun-R.,Zhao, Yanxing,et al. Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension[J]. CURRENT MEDICAL RESEARCH AND OPINION,2008,24(10):2863-2871.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sun, Ning-L.]'s Articles
[Zhu, Jun-R.]'s Articles
[Zhao, Yanxing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sun, Ning-L.]‘s Articles
[Zhu, Jun-R.]‘s Articles
[Zhao, Yanxing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace